AstraZeneca Korea Completes Reorganization of Business Units

With the total revenue surpassing over 100 billion won from last year, AstraZeneca Korea recently completed a reorganization of company functions under its plan to drive growth on a long-term basis.

According to the company spokesperson, the stated reorganization effort has generated a formation of three major pharmaceutical business units - the circulatory business unit, the anti-cancer bus...